Athira pharma to present updates from phase 2/3 trials of ath-1017 at the 2021 clinical trials on alzheimer's disease (ctad) conference

Bothell, wash., sept. 29, 2021 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that updates and baseline data from two ongoing phase 2 and phase 2/3 clinical trials of its lead development candidate ath-1017, a novel small molecule therapeutic specifically designed to enhance the activity of hepatocyte growth factor (hgf) and its receptor met, in mild-to-moderate alzheimer's disease, will be presented as an oral presentation at the upcoming 2021 clinical trials on alzheimer's disease (ctad) conference taking place nov. 9-12, 2021 both virtually and in-person in boston.
ATHA Ratings Summary
ATHA Quant Ranking